API | agn-195183

agn-195183 Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Chemistry

SMILES: CC1(C)CCC(C)(C)c2c(Cl)c(O)c(cc12)C(=O)Nc3cc(F)c(C(=O)O)c(F)c3
InChIKey: PNAWUIKCVQSLFG-UHFFFAOYSA-N
Mol. Mass: 437.87
ALogP: 5.62 Partition coefficient
ChEMBL Molecule:
nrx195183

More Chemistry

Pharmacology

Mechanism of Action:
- Retinoic acid receptor alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

agn-195183 | irx5183 | irx-5183 | nrx195183 | nrx 195183 | nrx-195183 | vtp195183 | vtp-195183

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)

Leukemia, Promyelocytic, Acute (Phase 2)

Lymphoma (Phase 1/Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue